


AMENDMENTS TO THE CLAIMS

1(original). A compound of Formula (I)



wherein

R^1 is hydrogen or (C_1-C_4) alkyl;

R^2 is hydrogen, $-C(O)R^{2a}$, $-C(O)-(CH_2)_n-R^{2b}$, or $-(CH_2)_m-R^{2c}$, where n is 0, 1 or 2, m is 0, 1, 2 or 3, R^{2a} is (C_1-C_4) alkyl or halo-substituted (C_1-C_4) alkyl, and R^{2b} and R^{2c} are $-NH(C_1-C_4)$ alkyl, $-N((C_1-C_4)alkyl)_2$, pyridinyl, hydroxy (C_1-C_4) alkyl, phenyl, or piperidinyl;

R^3 is (C_1-C_6) alkyl; and

X is carbonyl or methylene;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

2(original). The compound of Claim 1 wherein X is carbonyl; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

3(original). The compound of Claim 1 wherein X is methylene; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

4(original). The compound of Claim 2 or 3 wherein R^2 is $-C(O)-(CH_2)_n-$

R^{2b} ; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

5(original). The compound of Claim 4 wherein R^{2b} is pyridinyl; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

6(original). The compound of Claim 5 wherein R^{2b} is 3-pyridinyl or 4-pyridinyl; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

7(original). The compound of Claim 2 or 3 wherein R^2 is $-(CH_2)_m-R^{2c}$; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

8(original). The compound of Claim 7 wherein R^{2c} is $-NH(C_1-C_4)alkyl$ or $-N((C_1-C_4)alkyl)_2$; a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

9(original). The compound of Claim 1 selected from the group consisting of

9-amino-5-ethyl-5H-phenanthridin-6-one;

9-amino-5-isopropyl-5H-phenanthridin-6-one;

9-Amino-5-isobutyl-5H-phenanthridin-6-one;

N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2,2,2-trifluoro-acetamide;

N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-4-yl-acetamide;

2-dimethylamino-N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-

acetamide;

N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-3-piperidin-1-yl-

propionamide;

2-dimethylamino-N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-acetamide;

N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-4-yl-acetamide;

N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-3-piperidin-1-yl-propionamide;

N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-3-yl-acetamide;

N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-hydroxy-isobutyramide;

N-(5-ethyl-5,6-dihydro-phenanthridin-9-yl)-2,2,2-trifluoro-acetamide;

9-(3-dimethylamino-propylamino)-5-ethyl-5H-phenanthridin-6-one; and

9-benzylamino-5-ethyl-5H-phenanthridin-6-one;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

10(original). The compound of Claim 4 selected from the group consisting of

N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2,2,2-trifluoro-acetamide;

N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-4-yl-acetamide;

2-dimethylamino-N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-acetamide;

N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-3-piperidin-1-yl-propionamide;

2-dimethylamino-N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-acetamide;

N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-4-yl-acetamide;

N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-3-piperidin-1-yl-propionamide;

N-(5-isopropyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-pyridin-3-yl-acetamide;

N-(5-ethyl-6-oxo-5,6-dihydro-phenanthridin-9-yl)-2-hydroxy-isobutyramide;
and

N-(5-ethyl-5,6-dihydro-phenanthridin-9-yl)-2,2,2-trifluoro-acetamide;
a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said
compound or said salt.

11(original). The compound of Claim 7 selected from the group consisting
of

9-benzylamino-5-ethyl-5H-phenanthridin-6-one; and

9-(3-dimethylamino-propylamino)-5-ethyl-5H-phenanthridin-6-one;
a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said
compound or said salt.

12(currently amended). A pharmaceutical composition comprising a
compound of ~~any one of the preceding claims~~ Claim 1 and a pharmaceutically
acceptable excipient, diluent, or carrier.

13(currently amended). The pharmaceutical composition of Claim 12
further comprising at least one additional pharmaceutical agent selected from the
group consisting of an anti-obesity agent, an anorectic agent, a sorbitol
dehydrogenase inhibitor, an aldose reductase inhibitor, a glycogen
phosphorylase inhibitor, a cholinomimetic agent, an anti-depressant, an
antianxiolytic agent, and a typical or atypical antipsychotic agent.

14 (cancelled).

15(currently amended). A method for treating a disease, condition or
disorder modulated by a NPY-5 receptor antagonist in animals comprising the
step of administering to an animal in need of such treatment a therapeutically
effective amount of a compound of Claim 1, a pharmaceutically acceptable salt
thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said

compound, said salt or said prodrug, wherein said disease, condition or disorder is obesity, a feeding disorder, seizures, anxiety, diabetes, hypertension, hyperlipidemia, pancreatic or breast cancer, nasal congestion, female or male sexual dysfunction, congestive heart failure, an intestinal dysfunction, or a psychiatric disorder.

16(cancelled).